(Q42983413)

English

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

scientific article published on 21 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

I A Rowe

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D D Houlihan

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D J Mutimer

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

21 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

670-679

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Protease inhibitors for treatment of genotype 1 hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Antiviral strategies in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approach.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Liver stiffness diminishes with antiviral response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

The idolatry of the surrogate

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12018

21 January 2018

Identifiers

10.1111/APT.12018

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42983413&oldid=1975845415"